China's National Medical Products Administration (NMPA) approved Shanghai Junshi Biosciences' (HKG:1877) new drug application (NDA) for its cholesterol ongericimab injection, according to a Sunday filing with the Hong Kon bourse.
The drug is meant for the treatment of adult patients with primary hypercholesterolemia (non-familial) and mixed dyslipidemia.
The pharmaceutical stocks were down nearly 5% in Hong Kong and 1% in Shanghai in recent trading.
Price (HKD): $14.58, Change: $-0.72, Percent Change: -4.71%
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。